Patents by Inventor Sathibalan Ponniah
Sathibalan Ponniah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220347281Abstract: The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods.Type: ApplicationFiled: October 21, 2020Publication date: November 3, 2022Inventors: George E. PEOPLES, Sathibalan PONNIAH
-
Publication number: 20220241389Abstract: The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods.Type: ApplicationFiled: January 12, 2022Publication date: August 4, 2022Inventors: George E. PEOPLES, Sathibalan PONNIAH
-
Patent number: 11260118Abstract: The present invention relates to a peptide composition capable of binding with major histocompatibility complex class I molecules to induce an anti-cancer immune response in a subject. Particularly, the peptide composition comprises at least a Four-jointed Box 1 peptide and a Melanoma Antigen family D4b peptide. The present invention further relates to the use of a peptide composition and a peptide vaccine for inducing the anti-cancer immune response in the subject.Type: GrantFiled: March 15, 2018Date of Patent: March 1, 2022Assignee: Cancer Research MalaysiaInventors: San Jiun Chai, Sammuel Chee Yong Fong, Chai Phei Gan, Sathibalan Ponniah, Vyomesh Patel, Sok Ching Cheong, Kue Peng Lim
-
Patent number: 10842856Abstract: The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods.Type: GrantFiled: March 5, 2018Date of Patent: November 24, 2020Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: George E. Peoples, Sathibalan Ponniah
-
Publication number: 20200138929Abstract: The present invention relates to a peptide composition capable of binding with major histocompatibility complex class I molecules to induce an anti-cancer immune response in a subject. Particularly, the peptide composition comprises at least a Four-jointed Box 1 peptide and a Melanoma Antigen family D4b peptide. The present invention further relates to the use of a peptide composition and a peptide vaccine for inducing the anti-cancer immune response in the subject.Type: ApplicationFiled: March 15, 2018Publication date: May 7, 2020Inventors: San Jiun CHAI, Sammuel Chee Yong FONG, Chai Phei GAN, Sathibalan PONNIAH, Vyomesh PATEL, Sok Ching CHEONG, Kue Peng LIM
-
Publication number: 20190060429Abstract: The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods.Type: ApplicationFiled: March 5, 2018Publication date: February 28, 2019Inventors: George E. PEOPLES, Sathibalan PONNIAH
-
Patent number: 9737596Abstract: Provided are methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, GP2, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission, including patients having low to intermediate levels of HER2/neu expression. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as GM-CSF, and the GP2 peptide. The methods may further comprise administering a periodic booster vaccine dose as needed due to declining GP2-specific T cell immunity. Also provided are vaccine compositions for use in the methods.Type: GrantFiled: July 30, 2015Date of Patent: August 22, 2017Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: George Peoples, Sathibalan Ponniah
-
Patent number: 9720000Abstract: This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific and/or enhanced expression only in the presence of the antibody.Type: GrantFiled: May 15, 2015Date of Patent: August 1, 2017Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Sathibalan Ponniah, George E Peoples, Catherine E Storrer, Michael Flora
-
Publication number: 20160258951Abstract: The human HLA-A2:1g dimer molecule is a recombinant protein comprising a mouse IgG antibody fused with two human MHC Class I HLA-A2 molecules. Any peptide (usually 8-10 amino acids in length) can be loaded into the peptide-binding groove of the two HLA molecules, for example, by incubating a mixture of the dimer and peptide solution overnight. The resulting N peptide-specific HLA-A2:1g dimer mixture can then be added to PBMCs from peripheral blood samples in order to detect CD8 T lymphocytes which express T cell receptors that are capable of specifically interacting with and binding to the peptide HLA-A2:1g dimer molecules. The presence of such specific binding activity and interactions can then be detected by additional staining with fluorescence-conjugated antibodies.Type: ApplicationFiled: October 28, 2014Publication date: September 8, 2016Inventors: Sathibalan Ponniah, George E. Peoples, Catherine Storrer
-
Patent number: 9370560Abstract: The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods.Type: GrantFiled: July 9, 2014Date of Patent: June 21, 2016Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: George E. Peoples, Sathibalan Ponniah
-
Publication number: 20160022790Abstract: Provided are methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, GP2, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission, including patients having low to intermediate levels of HER2/neu expression. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as GM-CSF, and the GP2 peptide. The methods may further comprise administering a periodic booster vaccine dose as needed due to declining GP2-specific T cell immunity. Also provided are vaccine compositions for use in the methods.Type: ApplicationFiled: July 30, 2015Publication date: January 28, 2016Inventors: George Peoples, Sathibalan Ponniah
-
Publication number: 20150260727Abstract: This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific and/or enhanced expression only in the presence of the antibody.Type: ApplicationFiled: May 15, 2015Publication date: September 17, 2015Inventors: Sathibalan Ponniah, George E. Peoples, Catherine E. Storrer, Michael Flora
-
Patent number: 9114099Abstract: Provided are methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER/neu oncogene, GP2, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission, including patients having low to intermediate levels of HER2/neu expression. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as GM-CSF, and the GP2 peptide. The methods may further comprise administering a periodic booster vaccine dose as needed due to declining GP2-specific T cell immunity. Also provided are vaccine compositions for use in the methods.Type: GrantFiled: December 9, 2009Date of Patent: August 25, 2015Assignee: The Henry M. Jackson Foundation for the Advancement of Miltary Medicine, Inc.Inventors: George Peoples, Sathibalan Ponniah
-
Publication number: 20150182609Abstract: The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods.Type: ApplicationFiled: July 9, 2014Publication date: July 2, 2015Inventors: George E. PEOPLES, Sathibalan PONNIAH
-
Patent number: 9050322Abstract: This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific and/or enhanced expression only in the presence of the antibody.Type: GrantFiled: February 22, 2013Date of Patent: June 9, 2015Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Sathibalan Ponniah, George E Peoples, Catherine E Storrer, Michael Flora
-
Patent number: 8945573Abstract: This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific and/or enhanced expression only in the presence of the antibody.Type: GrantFiled: March 10, 2008Date of Patent: February 3, 2015Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Sathibalan Ponniah, George E. Peoples, Catherine E. Storrer, Michael Flora
-
Patent number: 8883164Abstract: This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific and/or enhanced expression only in the presence of the antibody.Type: GrantFiled: December 23, 2011Date of Patent: November 11, 2014Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Sathibalan Ponniah, George E. Peoples, Catherine E. Storrer, Michael Flora
-
Patent number: 8796220Abstract: The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods.Type: GrantFiled: June 27, 2012Date of Patent: August 5, 2014Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: George Peoples, Sathibalan Ponniah
-
Publication number: 20130189290Abstract: The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods.Type: ApplicationFiled: June 27, 2012Publication date: July 25, 2013Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: George PEOPLES, Sathibalan PONNIAH
-
Publication number: 20120107311Abstract: This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific and/or enhanced expression only in the presence of the antibody.Type: ApplicationFiled: December 23, 2011Publication date: May 3, 2012Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Sathibalan Ponniah, George E. Peoples, Catherine E. Storrer, Michael Flora